What Phase Is Retatrutide In? Phase 3 Trials and the TRIUMPH Programme Explained

Retatrutide is currently in Phase 3 clinical development.

That is the straightforward answer to one of the most commonly asked questions surrounding the investigational triple receptor agonist.

However, Retatrutide’s clinical development programme is considerably larger than a single Phase 3 trial.

Multiple Phase 3 studies are investigating Retatrutide across obesity, type 2 diabetes and several obesity-related complications, while other studies are examining longer-term cardiovascular and kidney outcomes.

Several pivotal Phase 3 results have now also been announced.

So what exactly does “Phase 3” mean, what is the TRIUMPH programme, and how close is Retatrutide to completing clinical development?

What Phase Is Retatrutide Currently In?

As of August 2026, Retatrutide is in Phase 3 clinical trials.

Retatrutide, also known by its development identifier LY3437943, is an investigational GIP, GLP-1 and glucagon receptor agonist developed by Eli Lilly and Company.

Phase 3 represents one of the final major stages of clinical investigation before a medicine can potentially be submitted to regulatory authorities for approval.

Importantly, being in Phase 3 does not mean that Retatrutide is already an approved medicine.

It remains investigational.

Has Retatrutide Completed Phase 3?

Some individual Phase 3 Retatrutide studies have now produced topline results, while other Phase 3 studies remain ongoing.

This distinction is important.

A drug development programme can contain numerous Phase 3 trials investigating different populations, outcomes and research questions.

In May 2026, Eli Lilly announced Phase 3 results from TRIUMPH-1, a pivotal study involving adults with obesity or overweight and at least one weight-related comorbidity without diabetes.

In July 2026, Lilly subsequently announced Phase 3 results from TRIUMPH-2 and TRIUMPH-3.

At the same time, additional Retatrutide trials remain underway.

Therefore, saying simply that “Phase 3 is finished” would not accurately describe the entire clinical development programme.

What Is the Retatrutide TRIUMPH Programme?

TRIUMPH is the name associated with a major programme of Phase 3 clinical research investigating Retatrutide.

Rather than relying on one study, researchers are evaluating the compound across different participant populations and clinical questions.

This provides evidence about how an investigational compound behaves under different research conditions.

The programme includes studies investigating areas such as:

• obesity and overweight
• type 2 diabetes
• severe obesity
• cardiovascular disease
• knee osteoarthritis-related outcomes
• obstructive sleep apnoea
• maintenance of weight reduction
• cardiovascular and kidney outcomes
• different dose-escalation approaches

This breadth illustrates why the phrase “the Retatrutide trial” can be misleading.

There are multiple Retatrutide trials.

What Was TRIUMPH-1?

TRIUMPH-1 is a Phase 3 study investigating Retatrutide in adults with obesity or overweight and at least one weight-related comorbidity without diabetes.

Eli Lilly announced positive topline Phase 3 results from TRIUMPH-1 in May 2026.

The study represented an important milestone because it provided pivotal Phase 3 evidence from a large obesity population.

However, one successful trial does not automatically complete the entire development or regulatory process.

Evidence from the wider clinical programme must also be considered.

What Is TRIUMPH-2?

TRIUMPH-2 investigated Retatrutide in adults with obesity or overweight and type 2 diabetes.

Lilly announced topline Phase 3 results from the study in July 2026.

This population is scientifically important because metabolic outcomes can differ between individuals with and without type 2 diabetes.

Studying different populations therefore helps researchers understand the compound more comprehensively.

What Is TRIUMPH-3?

TRIUMPH-3 is another Phase 3 study.

It investigated Retatrutide in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes.

Topline Phase 3 results were announced in July 2026.

The study expands the research beyond body weight alone by examining Retatrutide within a population already affected by significant cardiovascular disease.

What Is TRIUMPH-5?

TRIUMPH-5 is particularly interesting because it directly compares Retatrutide with Tirzepatide in adults with obesity.

Rather than comparing Retatrutide only with placebo, this study provides a head-to-head comparison between two different multi-receptor agonist strategies.

Tirzepatide primarily activates GIP and GLP-1 receptors.

Retatrutide activates GIP, GLP-1 and glucagon receptors.

TRIUMPH-5 therefore has the potential to provide particularly useful information about these two different receptor approaches.

What Is TRIUMPH-Outcomes?

TRIUMPH-Outcomes is a large Phase 3 study investigating cardiovascular and kidney outcomes.

The study includes adults living with obesity who also have established atherosclerotic cardiovascular disease and/or chronic kidney disease.

Unlike shorter studies concentrating predominantly on changes over months, an outcomes trial investigates major clinical events over a much longer period.

The study is expected to involve approximately 10,000 participants and continue for several years.

This makes it an important part of the longer-term Retatrutide research programme.

Are There Other Retatrutide Phase 3 Trials?

Yes.

The programme has continued to expand.

For example, TRIUMPH-6 investigates the maintenance of weight reduction.

TRIUMPH-8 investigates Retatrutide in participants with obesity or overweight without type 2 diabetes.

TRIUMPH-9 is a Phase 3b study investigating different Retatrutide dose-escalation schemes.

Some of these later studies are expected to continue beyond the earliest potential regulatory submissions.

This demonstrates an important principle of pharmaceutical development:

Clinical research does not necessarily stop when the first regulatory application is submitted.

Additional studies can continue investigating different questions, populations and longer-term outcomes.

What Does Phase 3 Mean?

Clinical development is generally divided into several stages.

Phase 1

Early human research generally focuses heavily on safety, tolerability, pharmacokinetics and how a compound behaves within the body.

Phase 2

Phase 2 studies expand the number of participants and investigate areas such as biological effects, dose-response relationships and safety.

Retatrutide’s Phase 2 obesity research attracted considerable scientific attention and helped support progression into larger studies.

Phase 3

Phase 3 studies generally involve substantially larger populations.

They are designed to provide more robust evidence concerning efficacy and safety and frequently form a major part of the evidence considered by regulatory authorities.

Retatrutide has now reached this stage.

What Happens After Phase 3?

Successful Phase 3 results do not automatically result in approval.

The developer must compile the relevant evidence and submit an application to the appropriate regulatory authority.

Regulators then review areas including:

• clinical efficacy
• safety
• manufacturing
• product quality
• benefit-risk balance
• proposed labelling
• supporting clinical evidence

Regulators can approve an application, request further information or decline it.

Therefore, completing pivotal Phase 3 studies and receiving regulatory approval are separate milestones.

When Could Retatrutide Be Submitted for Approval?

Eli Lilly stated in July 2026 that it plans to submit a Biologics License Application to the US Food and Drug Administration in the first quarter of 2027.

This is a planned submission rather than an approval date.

The timing of any subsequent regulatory decision depends on the review process and cannot be assumed in advance.

Regulatory timelines may also differ between countries.

Is Retatrutide FDA Approved?

No.

As of August 2026, Retatrutide remains investigational and has not been approved by the US Food and Drug Administration.

Phase 3 results should therefore not be confused with regulatory approval.

Is Retatrutide Approved in the UK?

Retatrutide remains investigational.

Any future UK authorisation would require the relevant regulatory process.

Clinical trial progress elsewhere does not automatically constitute UK marketing authorisation.

Why Are There So Many Retatrutide Trials?

A single clinical trial cannot answer every question about an investigational compound.

Different studies can investigate different:

• participant populations
• health conditions
• treatment durations
• endpoints
• comparator treatments
• dosing approaches
• safety questions

This is why large clinical development programmes can contain numerous studies running simultaneously.

The Retatrutide programme illustrates this clearly.

Is Retatrutide Still Experimental?

Yes.

“Investigational” is the more precise term.

Despite progressing through Phase 3 and producing results from several pivotal studies, Retatrutide has not yet completed the regulatory approval process.

That distinction is particularly important when interpreting online discussion surrounding the compound.

Frequently Asked Questions

What phase of clinical trials is Retatrutide in?

Retatrutide is in Phase 3 clinical development.

Has Retatrutide passed Phase 3?

Several Phase 3 studies have reported positive topline results, including TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3. However, the broader Phase 3 research programme contains additional ongoing studies.

Is Retatrutide approved yet?

No. Retatrutide remains an investigational compound.

What is the Retatrutide TRIUMPH trial?

TRIUMPH refers to a broader programme containing multiple Phase 3 Retatrutide studies rather than one individual trial.

Is Retatrutide being compared directly with Tirzepatide?

Yes. TRIUMPH-5 is a Phase 3 head-to-head study comparing Retatrutide with Tirzepatide in adults with obesity.

When will Retatrutide Phase 3 trials finish?

There is no single completion date because multiple trials are involved. Some have already produced pivotal results, while other studies are expected to continue for several years.

What happens after Retatrutide Phase 3?

Clinical evidence can be submitted to regulatory authorities for review. Lilly has stated that it plans an FDA submission for Retatrutide in Q1 2027.

Does successful Phase 3 research mean Retatrutide will definitely be approved?

No. Regulatory authorities independently evaluate the evidence before deciding whether a medicine should be authorised.

Where Retatrutide Stands in 2026

The Retatrutide development programme has now reached an important stage.

The compound is firmly within Phase 3 clinical development, and results from several pivotal studies have been announced.

At the same time, additional Phase 3 research remains underway, including head-to-head and longer-term outcomes studies.

The progression can therefore be understood as:

Phase 2 research → large Phase 3 programme → pivotal Phase 3 results → planned regulatory submission → regulatory review

Retatrutide has progressed substantially along that pathway, but it remains an investigational compound until the relevant regulatory authorities complete their review and grant any future authorisation.